Analyst firms · Wells Fargo · STRO
Wells Fargo STRO price target and rating history
Sutro Biopharma Inc. (STRO) · Health Care
Wells Fargo rates Sutro Biopharma Inc. (STRO) Overweight with a $49 price target, as of its latest action on Sep 30, 2026. It has published 4 rating actions on STRO since August 2022, including 1 upgrade and 1 downgrade. Across 9 firms with a STRO price target in the last 12 months, the median target is $49. Wells Fargo's target matches it.
- Current rating
- Overweight
- Price target
- $49
- Median target, all firms
- $49
- Actions on STRO
- 4
Wells Fargo price target on STRO
Every Wells Fargo rating on STRO
- Sep 30, 2026
- Mar 24, 2026
- Mar 21, 2023
- Aug 18, 2022
How other firms rate STRO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Overweight | $49 | Sep 30, 2026 |
| Stifel | Buy | $48 | Aug 7, 2026 |
| Truist Securities | Buy | $50 | Jun 11, 2026 |
| Barclays | Overweight | $56 | May 28, 2026 |
| Wedbush | Outperform | $60 | May 15, 2026 |
| Mizuho | Outperform | $50 | Apr 30, 2026 |
| Leerink Partners | Outperform | $38 | Apr 7, 2026 |
| H.C. Wainwright | Buy | $28 | Mar 24, 2026 |
| Citizens JMP | Mkt Outperform | $23 | Jan 20, 2026 |
Questions about Wells Fargo and STRO
- What is Wells Fargo's price target for STRO?
- Wells Fargo's latest stated price target for Sutro Biopharma Inc. (STRO) is $49, from its action on Sep 30, 2026.
- What is Wells Fargo's rating on STRO?
- Wells Fargo rates STRO Overweight, a bullish rating, as of Sep 30, 2026.
- When did Wells Fargo last change its view on STRO?
- On Sep 30, 2026, Wells Fargo resumes coverage at Overweight, price target $49.
- How does Wells Fargo's STRO target compare with other analysts?
- Across 9 firms with a STRO price target in the last 12 months, the median target is $49. Wells Fargo's target matches it.
All Wells Fargo ratingsSTRO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.